Acer Nigrum Whole Aesculus Hippocastanum Flower Al
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acer Nigrum Whole Aesculus Hippocastanum Flower Al
- Multi-Ingredient Botanical Formula: Insufficient Evidence for Repurposing Evaluation
Multi-Ingredient Botanical Formula: Insufficient Evidence for Repurposing Evaluation
One-Sentence Summary
This candidate consists of a 28-ingredient botanical/homeopathic combination (including Arnica Montana, American Ginseng, Aloe Vera, Capsicum, and other plant-derived materials), with no established original indication on record. The TxGNN model did not generate any predicted indications for this formula, and no clinical trials, literature evidence, or regulatory approvals were identified. At this stage, there is no actionable evidence to support a repurposing evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; in this case, no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The subject of this evaluation is not a single chemical entity but rather a 28-component botanical mixture, whose ingredients include:
- Flower extracts: Aesculus hippocastanum, Arnica montana, Borago officinalis, Nelumbo nucifera, Olea europaea, Prunella vulgaris, Prunus persica, Syringa vulgaris, Tropaeolum majus, Verbena officinalis, Zinnia elegans, Carpinus betulus, Cornus nuttallii, Fuchsia magellanica, Iris missouriensis, Rudbeckia hirta
- Whole-plant materials: Acer nigrum, Anagallis arvensis, Alfalfa, Umbellularia californica
- Functional ingredients: Aloe Vera, American Ginseng, Capsicum, Chaste Tree, Phosphoric Acid
- Alkaloid-containing botanicals: Strychnos nux-vomica seed (strychnine source), Ulmus procera
- Homeopathic salts: Quinine arsenite
TxGNN is trained to generate repurposing predictions for single active pharmaceutical ingredients (APIs) with known DrugBank identifiers. This formula has no DrugBank ID, no unified pharmacological mechanism, and no mapped disease nodes in the knowledge graph. As a result, the model pipeline could not produce a valid prediction output.
Additionally, complex multi-ingredient botanical or homeopathic mixtures present a fundamental challenge for AI-driven repurposing: their pharmacological activity cannot be reliably reduced to a single mechanism-of-action node in the TxGNN knowledge graph.
Safety Considerations
Please refer to the package insert for safety information.
Note on specific ingredients: Although no formal safety data was retrieved through the DDI pipeline, this formula contains ingredients that warrant attention:
- Strychnos nux-vomica seed contains strychnine, a potent alkaloid with a narrow therapeutic index.
- Quinine arsenite contains arsenic; chronic arsenic exposure carries well-documented toxicological risks.
- Capsicum (capsaicin) may cause mucosal irritation at higher concentrations.
Any clinical use evaluation should assess each ingredient individually for safety signals.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model requires a single, well-characterized API with a DrugBank ID to generate repurposing predictions. This 28-ingredient botanical/homeopathic formula does not meet that prerequisite, resulting in zero predictions, zero clinical evidence, and zero regulatory approvals in any queried jurisdiction.
To proceed, the following is needed:
- Clarify the active ingredient: Identify which of the 28 components is the intended focus for repurposing evaluation (e.g., if Capsicum/capsaicin or American Ginseng/ginsenoside is the primary agent, submit it as a standalone candidate).
- Resolve product identity: Obtain a DrugBank ID or equivalent structured identifier to enable TxGNN knowledge-graph mapping.
- Verify intended indication: Determine whether this formula has any historical use or clinical rationale that could guide a targeted evidence search.
- Conduct ingredient-level safety review: Each of the 28 components — particularly Strychnos nux-vomica and Quinine arsenite — should be individually assessed for safety before any further evaluation proceeds.
- Reassess pipeline eligibility: If this is a homeopathic product with no established pharmacological mechanism, it may fall outside the scope of AI-driven drug repurposing tools entirely.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.